Drug Trial Radar · NCT07603050
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
May 29, 2028
Study completion Aug 16, 2032
Sponsor
- Lead sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase I/II clinical study to evaluate the tolerance, safety and efficacy of VGN-R08b intracerebroventricular injection in patients with type III Gaucher's disease
Conditions
- Gaucher Disease Type 3
Interventions
VGN-R08bDrug
6×10\^10 vg/g
VGN-R08bDrug
1.2×10\^11 vg/g
VGN-R08bDrug
1.8×10\^11 vg/g
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events (AE), Serious adverse events (SAE)Time frame: Up to 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.